Company Encyclopedia
View More
name
abrdn Healthcare Investors
HQH.US
News
View More

Cantor Fitzgerald Remains a Buy on Regeneron (REGN)

Cantor Fitzgerald analyst Carter Gould maintained a Buy rating on Regeneron with a $740 price target. Regeneron's shares closed at $702.75. The analyst has a 5.5% average return and a 51.61% success rate. Regeneron has a Moderate Buy consensus with a $742 price target, indicating a 5.59% upside. Evercore ISI also maintained a Buy rating with a $750 target.

Tip Ranks·
US
REGN
0.00%
Tip Ranks·
US
REGN
0.00%

PKS Advisory Services LLC Increases Position in Eli Lilly and Company $LLY

PKS Advisory Services LLC increased its holdings in Eli Lilly and Company by 53.8% in Q2, owning 932 shares worth $726,000. Other funds also adjusted their positions in Eli Lilly. Analysts have set new price targets, with an average rating of "Moderate Buy" and a target price of $1,027.95. Eli Lilly's Q3 earnings exceeded expectations, with a 53.9% revenue increase year-over-year.

Market Beat·
US
LLY
0.00%
Market Beat·
US
LLY
0.00%

08:05 ET Accord BioPharma, Inc. Announces FDA Approval of Denosumab Biosimilars OSVYRTI® (denosumab-desu) and JUBEREQ® (denosumab-desu)

Accord BioPharma, a division of Intas Pharmaceuticals, announced FDA approval for two denosumab biosimilars, OSVYRTI® and JUBEREQ®. These biosimilars, comparable to Amgen's Prolia® and Xgeva®, are approved for treating osteoporosis and bone-related conditions from cancer. The approval marks Accord's fourth and fifth biosimilars, expanding their U.S. market presence. Clinical trials confirmed their similarity in efficacy and safety to reference products. Accord plans to commercialize these biosimilars by 2026, aiming to reduce treatment costs and enhance accessibility.

prnewswire·
US
AMGN
0.00%
prnewswire·
US
AMGN
0.00%

Zacks Research Has Bullish Forecast for LLY Q4 Earnings

Zacks Research has raised its Q4 2025 earnings per share estimate for Eli Lilly to $7.00, up from $6.83. The consensus full-year earnings estimate is $23.48 per share. Eli Lilly's recent earnings beat expectations, reporting $7.02 EPS against a $6.42 estimate, with revenue of $17.60 billion. The stock has a consensus rating of "Moderate Buy" and an average target price of $1,027.95. Institutional investors hold 82.53% of the stock.

Market Beat·
US
LLY
0.00%
Market Beat·
US
LLY
0.00%

Daily pill helps people lose 10% of weight in 18 months: study

A new daily pill developed by Eli Lilly, called orforglipron, helps people lose around 10% of their body weight over 18 months, according to a study published in The Lancet. This pill, which is cheaper and easier to take than current weight loss drugs, could be available by 2026 if approved by the FDA. The study involved over 1,500 adults with obesity and type 2 diabetes. Side effects include nausea, vomiting, constipation, and diarrhea.

Yahoo Finance·
US
LLY
0.00%
Yahoo Finance·
US
LLY
0.00%